Skip to Main Content

Paper Details

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Nat Commun
68
2018
ALRN-6924, B-cell and myeloid malignancies, IKZF1, JAK2, MDM2, MDMX, PDX models, PDXs, T, T- and NK-cell, T- and NK-cell lymphomas, TCL, TCLs, TP53, TP53-wild, TP53-wild-type TCLs, TP53-wild-type angioimmunoblastic T-cell lymphoma, lymphoid malignancies, p53, patient, romidepsin
Author NameAffiliation
Amanda L ChristieDana-Farber Cancer Institute
Mahmoud GhandiBroad Institute of Harvard and MIT
Mark A MurakamiDana-Farber Cancer Institute
Brian J HaasBroad Institute of Harvard and MIT
Brian J HaasBroad Institute of Harvard and MIT
Galen F GaoBroad Institute of Harvard and MIT
Andrew D CherniackBroad Institute of Harvard and MIT
Andrew D CherniackBroad Institute of Harvard and MIT
Aaron R ThornerCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
David M DorfmanHarvard Medical School
David M DorfmanBrigham and Women's Hospital
Aviad TsherniakBroad Institute of Harvard and MIT
Aviad TsherniakBroad Institute of Harvard and MIT
David E RootBroad Institute of Harvard and MIT
David E RootBroad Institute of Harvard and MIT
Francisca VazquezBroad Institute of Harvard and MIT
William C HahnDana-Farber Cancer Institute
William C HahnHarvard Medical School
William C HahnBroad Institute of Harvard and MIT
William C HahnDana-Farber Cancer Institute
William C HahnBroad Institute of Harvard and MIT
William C HahnHarvard Medical School
Giorgio InghiramiWeill Cornell Medical College
David M WeinstockDana-Farber Cancer Institute
David M WeinstockBroad Institute of Harvard and MIT
David M WeinstockHarvard Medical School
  • 1 - 26

Datasets

Release 1.2